http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
통신망에서 MPEG 영상 전송을 위한 QoS 측정 및 평가에 관한 연구
서재철,Suh Jae-Chul 한국디지털콘텐츠학회 2002 한국디지털콘텐츠학회논문지 Vol.3 No.1
인터넷을 중심으로 최근의 네트워크의 발전은 데이터 전송량의 범위를 멀티미디어 정보까지 확대시킴에 따라 멀티미디어 서비스를 보장하기 위해서 기존 인터넷의 Best Effort service에서 제공하지 못하는 end-to-end QoS(Quality of Service)의 제공이 필수적이다. 이를 위해 일정한 수준의 대역폭, 전송지연, 지연변이, 데이터 손실률 등의 network parameter 뿐만 아니라 시스템 내에서도 일정 수준의 CPU time 이나 메모리를 보장해 주어야 한다. 이에 따라 한정된 자원 안에서 멀티미디어 데이터를 분산시켜 네트워크 자원을 효율적으로 관리하기 위해 네트워크 자원 상황에 따라 적절하게 서비스 레벨을 조절하는 QoS 기반 통신 미들웨어의 개발이 시급하다. 또한 네트워크 시스템 및 application 개발자의 입장에서는 이를 구현하기 위해 실제 사용자가 느끼고 평가하게 되는 QoS의 객관적이고 사실적인 측정이 절실히 요구된다. 이를 위해 ATM 망상에서 보다 편리한 QoS 측정장치를 개발하고 또한 이러한 측정기술을 바탕으로 데이터를 추출하여 향상된 QoS를 제공하기 위한 개선된 미들웨어의 실질적인 메커니즘 개발과 검증에 적용한다. Lately development of network around Internet expands range of data traffic to multimedia information, and so for the guarantee of multimedia services end-to-end QoS(Quality of Service) must service because comparing with existing Internet service can not support For satisfying those QoS requirements, network have to guarantee not only network on parameter, such as delay, jitter, throughput but also system resources like CPU utilization, memory usage. Therefore it is urgent to develop QoS based middleware to distribute multimedia data and maximize network utilization in the limited resource environment. And it must be necessary of network to provide end-to-end QoS(Quality of Service) for multimedia applications. Multimedia applications want that QoS which satisfy their own service properties be guaranteed Then, We must analyze those necessary QoS requirements md define QoS parameter which specify as two viewpoint, user's and network's perspective. Therefore network provider supplying network for usual user and university, enterprise must want to find about their own network performance and problem. It is essential for network manager to want to use a tool like this. On the basis of technique about QoS test-bed in the AIM network, We studied on the method of QoS measurement and management about end-to-end connection in the Internet. We measured network status about end-to-end connection and analyze the result of performance.
폐암 환자에서 면역조직화학 염색을 통한 p53, erbB-2, CEA 종양단백 발현과 임상적 의의
강동원 ( Dong Won Kang ),이규승 ( Gyu Seung Lee ),김선영 ( Sun Young Kim ),김주옥 ( Ju Ock Kim ),정성수 ( Seong Su Jeong ),고동석 ( Dong Seok Ko ),서재철 ( Jae Chul Suh ),김근화 ( Geun Hwa Kim ),신경상 ( Kyoung Sang Shin ),송규상 대한결핵 및 호흡기학회 1998 Tuberculosis and Respiratory Diseases Vol.45 No.4
폐결핵 진단을 위한 STAT-PAK ULTRA FAST(R)와 ICT Tuberculosis(R)의 유용성에 관한 연구
김근화 ( Geun Hwa Kim ),박희선 ( Hee Sun Park ),김명훈 ( Myung Hoon Kim ),강동원 ( Dong Won Kang ),이규승 ( Kyu Seung Lee ),고동석 ( Dong Seok Ko ),서재철 ( Jae Chul Suh ),정성수 ( Seong Su Jeong ),김주옥 ( Ju Ock Kim ),김선영 ( S 대한결핵 및 호흡기학회 1999 Tuberculosis and Respiratory Diseases Vol.47 No.3
서재철,김명훈,박희선,강동원,이규승,고동석,김근화,정성수,김형주,송규상,김주옥,김선영 충남대학교 의과대학 지역사회의학연구소 2000 충남의대잡지 Vol.27 No.2
Cutaneous metastases from internal malignancy are uncommon. The frequency of metastases to the skin varies from 0.5-10%. Certain malignancy are more frequently associated than others with skin metastases. In men, the primary malignancy is most often found in the lung, in women, the most common primary malignancy is in the breast. The frequency of cutaneous metastasis from lung cancer varies from 0.7-3.1%. The incidence of cutaneous metastases is high for the large cell carcinomas and low for the squamous cell and small cell carcinomas. We report here a case of cutaneous metastasis from squamous cell lung cancer in a 60 year old male patient who has erythematous nodule on his finger. Biopsy specimen from the nodule showed squamous cell carcinoma like the primary lung cancer. We have reviewed the literature.
고동석,김명훈,박희선,강동원,이규승,서재철,김근화,정성수,김주옥,김선영 충남대학교 의과대학 지역사회의학연구소 2000 충남의대잡지 Vol.27 No.2
Background: Chemotherapy and radiotherapy have been main treatment methods of small cell lung cancer(SCLC). Recently, however, surgical therapy applied to SCLC stage I and II according to the TNM stage system. Veterans Administration Lung Cancer Study Group(VALG) for SCLC have combined limited- and extensive-stage that have not included anatomic staging information. We performed this study to examine the possible benefit of TNM staging included anatomic staging information in the SCLC. Method: We retrospectively reviewed medical records and computed tomography (CT) of 157 patients (133 men and 15 women: median age, 60 years: range, 33-78 years) with small cell lung cancer (SCLC). The survival according to TNM stage and classification of Veterans Administration Lung Cancer Study Group (VALG) was analyzed. Results: Eighty two patients had extensive stage (ES) and 75 patients had limited stage (LS). The median survival of each stage was 390 days and 300 days (p<0.05). Three patients had Stage la, 5 patients, stage Ib; 0 patients, stage Ila; 11 patients, stage IIb; 32 patients, stage IIIa; 42 patients, stage IIIb; 64 patients, stage IV. The median survival of patients according to TNM staging system was 1022 days in stage Ib, 425 days in stage IIb, 396 days in stage IIIa, 390 days in stage IIIb, and 240 days in stage IV Conclusion: Revised TNM stage system included anatomic staging information is useful to estimate prognosis and survival of SCLC.
IIIA 병기의 비소세포 폐암 환자에서 술전 유도화학요법의 임상적 효과
강동원,이규승,김선영,김주옥,정성수,고동석,서재철,김근화 대한내과학회 1999 대한내과학회지 Vol.57 No.2
Background: Surgical therapy remains the only curative treatment of localized non-small cell lung cancer(NSCLC). But the efficacy of surgery for patients with NSCLC is limited, although recent studies suggest that neoadjuvant chemotherapy may improve survival. Many studies also demonstrated benefit for neoadjuvant therapy. However very few studies about neoadjuvant chemotherapy were reported in Korea. We conducted this study to examine the possible benefit of neoadjuvant chemotherapy in patients with operable stage IIIA NSCLC. Methods : Twenty seven patients(25 men and 2 women) with clinical stage IIIA NSCLC were analyzed. The patients received 2 to 4 courses of cisplatin based chemotherapy and followed by surgery. To compare the resection rate and survival, 12 patients(10 men, 2 women) with clinical stage IIIA and initially treated operation were also anayzed. Results: The radiologically assessed response rate to the neoadjuvant therapy was 59.3%. Twelve seven patients underwent gross tumor resection with 24(88.9%) having complete resection and 21(77.8%) having postaperative stage I ar II. Pathologically defined response in nodal staging was more higher(85.2%). There was no difference of relapse free interval in recurred patients between two groups. But in patients treated with neoadjuvant therapy, distant recurrence is less higher than local recurrence. The median period of survival was 42 months in the patients treated with neoadjuvant therapy, and 27 months in the patients initially treated with surgery(p=0.287). Conclusion : The neoadjuvant chemotherapy improves local tumor control and lowers the distant recurrence. There was a possible trend improving median survival. So neoadjuvant chemotherapy might be considered as a standard therapy in stage IIIA NSCLC.